Market Place
Sourcing Support
Incyte’s $750M buyout rocked by pause on key trial, asset cull
18 Nov 2024 //
FIERCE BIOTECH
Incyte Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
07 Nov 2024 //
BUSINESSWIRE
Incyte wins injunction to block Sun`s Leqselvi launch
05 Nov 2024 //
FIERCE PHARMA
Incyte to Present at Upcoming Investor Conferences
30 Oct 2024 //
BUSINESSWIRE
Incyte raises 2024 sales forecast for top-selling drug Jakafi
29 Oct 2024 //
REUTERS
Incyte Reports Q3 2024 Financial Results and Updates
29 Oct 2024 //
BUSINESSWIRE
Incyte Named Top 5 Company On Science Magazine’s List
24 Oct 2024 //
BUSINESSWIRE
Incyte picks Dr. Pimple Popper to expand Opzelura campaign
14 Oct 2024 //
FIERCE PHARMA
Incyte Shares Atopic Dermatitis Patient Experiences
10 Oct 2024 //
BUSINESSWIRE
Incyte to Report Third Quarter Financial Results
08 Oct 2024 //
BUSINESSWIRE
Incyte Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
07 Oct 2024 //
BUSINESSWIRE
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2024 //
BUSINESSWIRE
Incyte To Present Dermatology Data At EADV 2024 Congress
25 Sep 2024 //
BUSINESSWIRE
Incyte & Syndax Publish AGAVE-201 Trial Data on Axatilimab in GVHD
18 Sep 2024 //
PR NEWSWIRE
Incyte CEO Sees Zynyz As Pipeline Aid Despite Unique Trial Win
14 Sep 2024 //
FIERCE PHARMA
Incyte`s Retifanlimab Extends PFS In Anal Carcinoma At ESMO 2024
14 Sep 2024 //
BUSINESSWIRE
Incyte`s CDK2 Inhibitor Shows Activity In Advanced Solid Tumors
14 Sep 2024 //
BUSINESSWIRE
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Sep 2024 //
BUSINESSWIRE
Incyte To Present Phase 3 Results For Retifanlimab At ESMO 2024
22 Aug 2024 //
BUSINESSWIRE
Incyte Seeks Monjuvi Label Expansion After Phase 3 Lymphoma Win
19 Aug 2024 //
FIERCE PHARMA
Incyte`s blood cancer drug succeeds late-stage trial
16 Aug 2024 //
REUTERS
Incyte Announces Positive Results From Tafasitamab Study In Follicular Lymphoma
15 Aug 2024 //
BUSINESSWIRE
Incyte, Syndax bag FDA approval for Niktimvo in graft-versus-host disease
15 Aug 2024 //
FIERCE PHARMA
Incyte And Syndax’s Niktimvo™ Approved By FDA For Chronic GVHD Treatment
14 Aug 2024 //
BUSINESSWIRE
Incyte to Present at Upcoming Investor Conferences
13 Aug 2024 //
BUSINESSWIRE
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Aug 2024 //
BUSINESSWIRE
Incyte touts 2 trial wins for PD-1 drug Zynyz, eyes comeback in anal cancer
31 Jul 2024 //
FIERCE PHARMA
Incyte Reports Q2 2024 Results And Clinical Program Updates
30 Jul 2024 //
BUSINESSWIRE
Incyte to Report Second Quarter Financial Results
09 Jul 2024 //
BUSINESSWIRE
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Jul 2024 //
BUSINESSWIRE
Silence breaks phase 1 data on blood disorder prospect
27 Jun 2024 //
FIERCE BIOTECH
Incyte Announces Final Results of Tender Offer
13 Jun 2024 //
BUSINESSWIRE
Incyte Announces Preliminary Results of Tender Offer
11 Jun 2024 //
BUSINESSWIRE
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
BUSINESSWIRE
Incyte builds out operations in home state of Delaware
21 May 2024 //
FIERCE PHARMA
Incyte To Highlight Oncology Data At ASCO 2024, EHA Congress
14 May 2024 //
BUSINESSWIRE
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
13 May 2024 //
BUSINESSWIRE
Incyte Reports Q1 2024 Results, Updates On Key Clinical Programs
30 Apr 2024 //
BUSINESSWIRE
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
24 Apr 2024 //
PRESS RELEASE
Incyte Biologic Zynyz (retifanlimab-dlwr) Receives Approval in the U.S.
22 Apr 2024 //
FDA
CMS & Incyte collaborate to develop vitiligo drug Povorcitinib in China
04 Apr 2024 //
BIOSPECTRUM ASIA
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29 Mar 2024 //
BUSINESSWIRE
Ironwood spies new frontier for $1B drug in exploratory trial
29 Mar 2024 //
FIERCE BIOTECH
Incyte`s oral Dupixent rival hits in midphase skin disease trial
12 Mar 2024 //
FIERCE BIOTECH
Incyte`s Opzelura scores in hidradenitis suppurativa study
11 Mar 2024 //
FIERCE PHARMA
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream
10 Mar 2024 //
BUSINESSWIRE
Incyte Presents Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib
10 Mar 2024 //
BUSINESSWIRE
New Data from Incyte’s Growing Dermatology Portfolio to be Presented
04 Mar 2024 //
BUSINESSWIRE
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of MPNs
29 Feb 2024 //
BUSINESSWIRE
Incyte Announces U.S. FDA Grants Priority Review for Axatilimab
27 Feb 2024 //
BUSINESSWIRE
Incyte To Present At Upcoming Investor Conference
15 Feb 2024 //
PRESS RELEASE
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results
13 Feb 2024 //
BUSINESSWIRE
Amid GSK showdown, Incyte crosses $1B in quarterly revenue
13 Feb 2024 //
FIERCE PHARMA
Incyte Gains Development and Commercialization Rights to Tafasitamab (Monjuvi®)
05 Feb 2024 //
BUSINESSWIRE
Exclusive: Reid Huber reunites with former Incyte colleague Wenqing Yao
24 Jan 2024 //
ENDPTS
Incyte vets raise $102M to create better PARP, PI3K drugs
24 Jan 2024 //
FIERCE BIOTECH
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
23 Jan 2024 //
BUSINESSWIRE
Incyte Highlights Growth Opportunities and Provides Business Updates
08 Jan 2024 //
BUSINESSWIRE
Incyte to Present at Upcoming Investor Conferences
12 Dec 2023 //
BUSINESSWIRE
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial
10 Dec 2023 //
BUSINESSWIRE
